How do you discuss use of tamoxifen in your stage I breast cancer patients who are > 80 years old weighing in risk of VTE with benefit from adjuvant treatment?

The risk of both thrombotic events and endometrial cancer are age-dependent in general - much of this information is best interpreted from the prevention literature, where the numbers are larger, and the impacts of co-morbidities and concomitant medications are less. With tamoxifen use, both the abs...